{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:25Z","timestamp":1790911225331,"version":"4.1.0"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>The most common thrombotic microangiopathy (TMA) of pregnancy is the well-recognized syndrome of preeclampsia with hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. However, rare TMAs, including thrombotic thrombocytopenic purpura, complement-mediated hemolytic-uremic syndrome, and catastrophic antiphospholipid syndrome, may occur during pregnancy or postpartum and present with features similar to those of preeclampsia with severe features. Early recognition and treatment of these infrequently encountered conditions are key for avoiding serious maternal morbidities with long-term sequelae and possible maternal or fetal death. Differentiating between preeclampsia with severe features and these rare TMAs is diagnostically challenging as there is significant overlap in their clinical and laboratory presentation. Given the rarity of these TMAs, high-quality evidence-based recommendations on diagnosis and management during pregnancy are lacking. Using current objective information and recommendations from working groups, this report provides practical clinical approaches to diagnose and manage these rare TMAs. This report also discusses how to manage individuals with a history of these rare TMAs who are planning to conceive. To optimize favorable outcomes, a multidisciplinary approach including obstetricians, maternal-fetal medicine specialists, hematologists, and nephrologists alongside close clinical and laboratory monitoring is vital.<\/jats:p>","DOI":"10.1097\/aog.0000000000005024","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T02:00:06Z","timestamp":1669946406000},"page":"85-108","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum"],"prefix":"10.1097","volume":"141","author":[{"given":"Ming Y.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhamed Yazan","family":"Abou-Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ware","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.AOG.0000258281.22296.de","article-title":"Imitators of severe preeclampsia","volume":"109","author":"Sibai","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AOG.0000000000004289","article-title":"Acute fatty liver of pregnancy","volume":"137","author":"Nelson","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2001-11-0060","article-title":"Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers","volume":"99","author":"Arya","year":"2002","journal-title":"Blood"},{"key":"R11-20250423","first-page":"57","article-title":"Shear stress-induced binding of von Willebrand factor to platelets","volume":"34","author":"Konstantopoulos","year":"1997","journal-title":"Biorheology"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation","volume":"78","author":"Moake","year":"1986","journal-title":"J Clin Invest"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/00001721-200310000-00005","article-title":"Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium","volume":"14","author":"Sanchez-Luceros","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1160\/TH03-11-0683","article-title":"von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women","volume":"92","author":"Sanchez-Luceros","year":"2004","journal-title":"Thromb Haemost"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/apm.12833","article-title":"Maternal vascular malperfusion of the placental bed","volume":"126","author":"Ernst","year":"2018","journal-title":"APMIS"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jca.21248","article-title":"Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency","volume":"27","author":"George","year":"2012","journal-title":"J Clin Apher"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.24665","article-title":"Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French Thrombotic Microangiopathies Reference Centre","volume":"92","author":"Grall","year":"2017","journal-title":"Am J Hematol"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.thromres.2020.05.045","article-title":"Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: a 10-year provincial retrospective cohort study","volume":"193","author":"Sawler","year":"2020","journal-title":"Thromb Res"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"R28-20250423","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.amjms.2016.05.003","article-title":"The alternative pathway of complement and the evolving clinical-pathophysiological spectrum of atypical hemolytic uremic syndrome","volume":"352","author":"Berger","year":"2016","journal-title":"Am J Med Sci"},{"key":"R29-20250423","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"key":"R30-20250423","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R31-20250423","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R32-20250423","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R33-20250423","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"R34-20250423","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R35-20250423","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"Jozsi","year":"2008","journal-title":"Blood"},{"key":"R36-20250423","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"Stahl","year":"2008","journal-title":"Blood"},{"key":"R37-20250423","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-1809.2009.00554.x","article-title":"Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome","volume":"74","author":"Sullivan","year":"2010","journal-title":"Ann Hum Genet"},{"key":"R38-20250423","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"R39-20250423","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"R40-20250423","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R41-20250423","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R42-20250423","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int"},{"key":"R43-20250423","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R44-20250423","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R45-20250423","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera","year":"2020","journal-title":"Lupus"},{"key":"R46-20250423","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.3390\/ijms22052588","article-title":"Understanding the pathophysiology of thrombotic APA through animal models","volume":"22","author":"Ghandi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R47-20250423","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"R48-20250423","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1055\/s-0035-1556725","article-title":"Antiphospholipid syndrome--not a noninflammatory disease","volume":"41","author":"de Groot","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"R49-20250423","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncprheum0432","article-title":"The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients","volume":"3","author":"Salmon","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R50-20250423","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"R51-20250423","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood.2020010575","article-title":"Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome","volume":"137","author":"Ruffatti","year":"2021","journal-title":"Blood"},{"key":"R52-20250423","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/jcm11030735","article-title":"Clinical management of thrombotic antiphospholipid syndrome","volume":"11","author":"Tumian","year":"2022","journal-title":"J Clin Med"},{"key":"R53-20250423","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"R54-20250423","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R55-20250423","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"R56-20250423","doi-asserted-by":"crossref","first-page":"e230863","DOI":"10.1136\/bcr-2019-230863","article-title":"Catastrophic antiphospholipid syndrome in pregnancy: a life-threatening condition","volume":"12","author":"Collict","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R57-20250423","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1080\/14767058.2018.1450381","article-title":"Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis","volume":"32","author":"Kozlovskaya","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R58-20250423","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bjh.12494","article-title":"ADAMTS13 deficiency in severe postpartum HELLP syndrome","volume":"163","author":"Pourrat","year":"2013","journal-title":"Br J Haematol"},{"key":"R59-20250423","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","article-title":"Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab","volume":"31","author":"Servais","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"R60-20250423","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2013-11-538900","article-title":"Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura","volume":"123","author":"Jiang","year":"2014","journal-title":"Blood"},{"key":"R61-20250423","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1681\/ASN.2016090995","article-title":"Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome","volume":"29","author":"Gaggl","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R62-20250423","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"key":"R63-20250423","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/HYPERTENSIONAHA.121.17311","article-title":"Differentiating hemolysis, elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period","volume":"78","author":"Burwick","year":"2021","journal-title":"Hypertension"},{"key":"R64-20250423","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"R65-20250423","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/jhh.2017.61","article-title":"Placental growth factor and pre-eclampsia","volume":"31","author":"Chau","year":"2017","journal-title":"J Hum Hypertens"},{"key":"R66-20250423","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/HYPERTENSIONAHA.121.17047","article-title":"PlGF (placental growth factor) testing in clinical practice: evidence from a Canadian tertiary maternity referral center","volume":"77","author":"McLaughlin","year":"2021","journal-title":"Hypertension"},{"key":"R67-20250423","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"R68-20250423","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"R69-20250423","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"R70-20250423","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/1471-0528.15855","article-title":"Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis","volume":"126","author":"Duhig","year":"2019","journal-title":"BJOG"},{"key":"R71-20250423","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/1471-0528.12259","article-title":"Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia","volume":"120","author":"Schnettler","year":"2013","journal-title":"BJOG"},{"key":"R73-20250423","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/jth.15009","article-title":"Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R74-20250423","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"R75-20250423","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood.2019000962","article-title":"How I treat thrombotic thrombocytopenic purpura in pregnancy","volume":"136","author":"Ferrari","year":"2020","journal-title":"Blood"},{"key":"R76-20250423","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/01.AOG.0000437385.88715.4a","article-title":"Definition of term pregnancy. Committee Opinion No. 579. American College of Obstetricians and Gynecologists","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R77-20250423","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"key":"R78-20250423","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/trf.13041","article-title":"Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count","volume":"55","author":"Riviere","year":"2015","journal-title":"Transfusion"},{"key":"R79-20250423","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R80-20250423","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R81-20250423","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/mrcr\/rxab051","article-title":"Rituximab administration during the second trimester of pregnancy for systemic lupus erythematosus: case report and review of the literature on rheumatic disease","volume":"6","author":"Colquhoun","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"R82-20250423","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.mbc.0000240918.65306.20","article-title":"Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura","volume":"17","author":"Scully","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R83-20250423","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"R84-20250423","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/bjh.17833","article-title":"First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy","volume":"196","author":"Kuhne","year":"2022","journal-title":"Br J Haematol"},{"key":"R85-20250423","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/IJWH.S282604","article-title":"Systemic lupus erythematosus management in pregnancy","volume":"14","author":"Dao","year":"2022","journal-title":"Int J Womens Health"},{"key":"R86-20250423","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"key":"R87-20250423","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"R88-20250423","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"R89-20250423","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"R90-20250423","first-page":"1215","article-title":"Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura","volume":"111","author":"Allford","year":"2000","journal-title":"Br J Haematol"},{"key":"R91-20250423","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura","volume":"135","author":"Scully","year":"2006","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"R92-20250423","first-page":"65","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"R93-20250423","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 content in plasma-derived factor VIII\/von Willebrand factor concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am J Hematol"},{"key":"R94-20250423","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"R95-20250423","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/imj.13804","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"48","author":"Fox","year":"2018","journal-title":"Intern Med J"},{"key":"R96-20250423","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"R97-20250423","first-page":"15","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives","volume":"5","author":"Blombery","year":"2014","journal-title":"J Blood Med"},{"key":"R98-20250423","first-page":"429","article-title":"Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP","volume":"82","author":"Bobbio-Pallavicini","year":"1997","journal-title":"Haematologica"},{"key":"R99-20250423","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2141.2003.04360.x","article-title":"Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura","volume":"121","author":"Yarranton","year":"2003","journal-title":"Br J Haematol"},{"key":"R100-20250423","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tmrv.2018.08.002","article-title":"Microangiopathic hemolytic anemia in pregnancy","volume":"32","author":"Neave","year":"2018","journal-title":"Transfus Med Rev"},{"key":"R101-20250423","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.14045","article-title":"How we manage thrombotic microangiopathies in pregnancy","volume":"173","author":"Thomas","year":"2016","journal-title":"Br J Haematol"},{"key":"R102-20250423","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/jth.15064","article-title":"Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura","volume":"18","author":"Sakai","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R103-20250423","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/hematology.2021000290","article-title":"How to evaluate and treat the spectrum of TMA syndromes in pregnancy","volume":"2021","author":"Scully","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R104-20250423","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ajh.24311","article-title":"Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy","volume":"91","author":"Epperla","year":"2016","journal-title":"Am J Hematol"},{"key":"R106-20250423","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jama.2021.8551","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"326","author":"Henderson","year":"2021","journal-title":"JAMA"},{"key":"R107-20250423","first-page":"e1","article-title":"Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196 [published erratum appears in Obstet Gynecol 2018;132:1068]. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R108-20250423","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"R109-20250423","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40620-021-01025-x","article-title":"Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis","volume":"34","author":"Fakhouri","year":"2021","journal-title":"J Nephrol"},{"key":"R110-20250423","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"R111-20250423","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-016-1946-x","article-title":"Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review","volume":"103","author":"Miyasaka","year":"2016","journal-title":"Int J Hematol"},{"key":"R112-20250423","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.kint.2019.01.012","article-title":"Placental passage of eculizumab and complement blockade in a newborn","volume":"95","author":"Duineveld","year":"2019","journal-title":"Kidney Int"},{"key":"R113-20250423","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.xkme.2019.12.004","article-title":"Successful pregnancies during ongoing eculizumab therapy in two patients with complement-mediated thrombotic microangiopathy","volume":"2","author":"Haninger-Vacariu","year":"2020","journal-title":"Kidney Med"},{"key":"R114-20250423","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","article-title":"The impact of eculizumab on routine complement assays","volume":"460","author":"Willrich","year":"2018","journal-title":"J Immunol Methods"},{"key":"R115-20250423","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv"},{"key":"R116-20250423","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"R118-20250423","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"R119-20250423","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12882-020-02190-0","article-title":"Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis","volume":"22","author":"Gackler","year":"2021","journal-title":"BMC Nephrol"},{"key":"R120-20250423","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R121-20250423","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16626","article-title":"The natural course of pregnancies in women with primary atypical haemolytic uraemic syndrome and asymptomatic relatives","volume":"190","author":"Timmermans","year":"2020","journal-title":"Br J Haematol"},{"key":"R122-20250423","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/AOG.0000000000003554","article-title":"Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review","volume":"135","author":"Gupta","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R123-20250423","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/AOG.0000000000003256","article-title":"Chronic kidney disease and pregnancy","volume":"133","author":"Hui","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R124-20250423","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","journal-title":"Arthritis Rheumatol"},{"key":"R125-20250423","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R126-20250423","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.41891","article-title":"Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome","volume":"73","author":"Erkan","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R127-20250423","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R128-20250423","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R129-20250423","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transpl"},{"key":"R130-20250423","doi-asserted-by":"crossref","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R131-20250423","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11239-014-1061-x","article-title":"Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss","volume":"38","author":"Mar","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"R132-20250423","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/asheducation-2017.1.144","article-title":"Thrombocytopenia in pregnancy","volume":"2017","author":"Cines","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:02:20Z","timestamp":1745431340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005024","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"2022-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}